Prot #APL2-302: A Phase III Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Project: Research project

Project Details

StatusActive
Effective start/end date1/30/191/30/22

Funding

  • Biorasi, LLC (Prot #APL2-302)
  • Apellis Pharmaceuticals, Inc. (Prot #APL2-302)